Electronic health record interventions at the point of care improve documentation of care processes and decrease orders for genetic tests commonly ordered by nongeneticists

Genetics in Medicine

Volumn 19, Issue 1, 2017, Pages 112-120

  Scheuner, Maren T ^a,b   Peredo, Jane ^a   Tangney, Kelly ^a   Schoeff, Diane ^a   Sale, Taylor ^a   Lubick Goldzweig, Caroline ^a,b   Hamilton, Alison ^a,b   Hilborne, Lee ^b,c   Lee, Martin ^a   Mittman, Brian ^a   Yano, Elizabeth M ^a,d   Lubin, Ira M ^e  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTRONIC HEALTH RECORD; GENETIC SCREENING; HOSPITAL; HUMAN; LOGISTIC REGRESSION ANALYSIS; MEDICAL RECORD REVIEW; STUDENT; DOCUMENTATION; FEMALE; GENETICS; MALE; POINT OF CARE SYSTEM; PROCEDURES; STANDARDS;

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; HEMOCHROMATOSIS PROTEIN; HFE PROTEIN, HUMAN; HLA B27 ANTIGEN;

DOCUMENTATION; ELECTRONIC HEALTH RECORDS; FACTOR V; FEMALE; GENETIC TESTING; HEMOCHROMATOSIS PROTEIN; HLA-B27 ANTIGEN; HUMANS; MALE; POINT-OF-CARE SYSTEMS;

EID: 85009209149     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.73     Document Type: Article

References (40)

1. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med 2013;15:258-267.
2. Scheuner MT, Marshall N, Lanto A, et al. Delivery of clinical genetic consultative services in the Veterans Health Administration. Genet Med 2014;16:609-619.
3. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008;299: 1320-1334.
4. Burke W, Culver J, Pinsky L, et al. Genetic assessment of breast cancer risk in primary care practice. Am J Med Genet A 2009;149A:349-356.
5. Brierley KL, Campfield D, Ducaine W, et al. Errors in delivery of cancer genetics services: implications for practice. Conn Med 2010;74:413-423.
6. Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med 2011;13:349-355.
7. Dhar SU, Cooper HP, Wang T, et al. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat 2011;129:221-227.
8. Plon SE, Cooper HP, Parks B, et al. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med 2011;13: 148-154.
9. Zhi M, Ding EL, Theisen-Toupal J, Whelan J, Arnaout R. The landscape of inappropriate laboratory testing: a 15-year meta-Analysis. PLoS One 2013;8:e78962.
10. Wood DL. Documentation guidelines: evolution, future direction, and compliance. Am J Med 2001;110:332-334.
11. National Committee for Quality Assurance. Guidelines for medical record documentation. http://www.ncqa.org/portals/0/policyupdates/supplemental/ guidelines-medical-record-review.pdf, Accessed 27 March 2016.
12. Lanktree MB, Lanktree BB, Paré G, Waye JS, Sadikovic B, Crowther MA. Examining the clinical use of hemochromatosis genetic testing. Can J Gastroenterol Hepatol 2015;29:41-45.
13. Adams PC. Epidemiology and diagnostic testing for hemochromatosis and iron overload. Int J Lab Hematol 2015;37 Suppl 1:25-30.
14. Laberge AM, Psaty BM, Hindorff LA, Burke W. Use of Factor V Leiden genetic testing in practice and impact on management. Genet Med 2009;11: 750-756.
15. Lane SK, Gravel JW Jr. Clinical utility of common serum rheumatologic tests. Am Fam Physician 2002;65:1073-1080.
16. Brandt HC, Spiller I, Song IH, Vahldiek JL, Rudwaleit M, Sieper J. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007;66:1479-1484.
17. Braun A, Gnann H, Saracbasi E, et al. Optimizing the identification of patients with axial spondyloarthritis in primary care-the case for a two-step strategy combining the most relevant clinical items with HLA B27. Rheumatology (Oxford) 2013;52:1418-1424.
18. Lubin IM, McGovern MM, Gibson Z, et al. Clinician perspectives about molecular genetic testing for heritable conditions and development of a clinician-friendly laboratory report. J Mol Diagn 2009;11:162-171.
19. Chen B, Gagnon M, Shahangian S, Anderson NL, Howerton DA, Boone JD; Centers for Disease Control and Prevention (CDC). Good laboratory practices for molecular genetic testing for heritable diseases and conditions. MMWR Recomm Rep 2009;58(RR-6):1-37; quiz CE.
20. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci 2009;4:50.
21. Scheuner MT, Hilborne L, Brown J, Lubin IM; members of the RAND Molecular Genetic Test Report Advisory Board. A report template for molecular genetic tests designed to improve communication between the clinician and laboratory. Genet Test Mol Biomarkers 2012;16:761-769.
22. Scheuner MT, Edelen MO, Hilborne LH, Lubin IM; RAND Molecular Genetic Test Report Advisory Board. Effective communication of molecular genetic test results to primary care providers. Genet Med 2013;15:444-449.
23. US Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006;145(3):204-208.
24. European Association for the Study of the Liver: EASLD clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
25. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002;126:1304-1318.
26. Spector EB, Grody WW, Matteson CJ, et al. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med 2005;7:444-453.
27. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007;92:1107-1114.
28. van den Berg R, de Hooge M, Rudwaleit M, et al. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Ann Rheum Dis 2013;72:1646-1653.
29. Aydin SZ, Maksymowych WP, Bennett AN, McGonagle D, Emery P, Marzo-Ortega H. Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. Ann Rheum Dis 2012;71:56-60.
30. Veteran Health Care Made Personal. Annual Report 2011. http://www. desertpacific.va.gov/DESERTPACIFIC/docs/VISN22-AR-2011-508-English-. pdf. Accessed 26 October 2015.
31. VA Desert Pacific Healthcare Network. Personalized Care for our Nation's Heroes. 2012 Annual Report. http://www.desertpacific.va.gov/DESERTPACIFIC/ docs/VISN22-AR-2012-508-English-.pdf. Accessed 26 October 2015.
32. 2013 Annual Report. VA Desert Pacific Healthcare Network. http://www. desertpacific.va.gov/DESERTPACIFIC/docs/VISN22-AR-2013-508-English-. pdf. Accessed 26 October 2015.
33. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA 2000;283: 1715-1722.
34. Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J. The effects of on-screen, point of care computer reminders on processes and outcomes of care. Cochrane Database of Systematic Reviews 2009; Issue 3. Art. No.: CD001096. doi:10.1002/14651858.CD001096.pub2.
35. Main C, Moxham T, Wyatt JC, Kay J, Anderson R, Stein K. Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems. Health Technol Assess 2010;14:1-227.
36. Scheuner MT, McNeel TS, Freedman AN. Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey. Genet Med 2010;12:726-735.
37. Vadaparampil ST, Wideroff L, Olson L, Viswanath K, Freedman AN. Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A 2005;135:41-46.
38. Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011;13:1-16.
39. Steinberg KK, Cogswell ME, Chang JC, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-2222.
40. Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum 2012;64:1407-1411.